Gastroenterology

NovaMedica and Ferring Pharmaceuticals, a Swiss-based global biopharmaceutical company, have signed an agreement, that gives NovaMedica the rights for commercialization of a range of Ferring’s line of innovative gastroenterological prescription drug products for the treatment of inflammatory bowel disease (IBD) in the Russian market. The product line includes established and soon-to-launch treatments for inflammatory bowel diseases: ulcerative colitis, Crohn's disease and bleeding from esophageal varices. More information about the agreement ... 

Currently, this segment of NovaMedica’s portfolio is represented by the following products: 


Cortiment – , a multi-matrix (MMX®) prolonged release budesonide, is indicated in adults for induction of remission in patients with mild to moderate active ulcerative colitis.

More information about the product...

Pentasa® is indicated for the induction and maintaining of remission in patients with mildly to moderately active ulcerative colitis and Crohn disease.

More information about the product...

Picoprep®  – is indicated to clean the bowel prior to X-ray examination or endoscopy, to clean the bowel prior to surgery when judged clinically necessary. PICOPREP® has approved dosing for children as of 9 year old and adults.

More information about the product...


All products passed Clinical Trials and registered in Russia.

PRODUCTS HAVE CONTRAINDICATIONS. PLEASE CONSULT A SPECIALIST BEFORE USE



 

Shareholders

Read more

Pipeline

Read more

Media Center

Read more